Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACK - Low-dose rivaroxaban for cardiovascular disease in advanced chronic kidney disease
2024-512483-59-00Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, coronary arteriosclerosis, arteriosclerosis obliterans and 3 more comparing Low-dose rivaroxaban with Placebo (2 arms). Primary endpoint: Primary composite cardiovascular outcome. Started Jun 2024; status: completed.
02
Drugs
rivaroxaban
03
Conditions
cardiac morbiditycoronary arteriosclerosisarteriosclerosis obliteransstrokechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-512483-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512483-59-00.